Letrozole Side Effects in PCOS: What the Trial Data Actually Show

How Often Do Letrozole’s Side Effects Actually Occur?

Fatigue was the single most-reported side effect of letrozole in the largest trial to measure it, affecting 34 of 110 women (30.9%) assigned to letrozole versus 8.1% on clomiphene in the same 220-woman randomized trial — nearly a four-fold difference. Hot flushes moved in the opposite direction: 31.8% on clomiphene versus 12.7% on letrozole. This page is the tolerability half of the letrozole story; for the mechanism and the live-birth numbers themselves, see why letrozole became the first-line ovulation drug, which this page does not repeat.

Three separate randomized trials have measured letrozole’s side-effect frequency against a comparator, and no two used quite the same design or the same list of symptoms — which is itself a finding worth knowing before trusting any single percentage below.

Read the “not measured” cells literally: the smaller two trials tracked only three to five specific symptoms each, so a blank cell means the trial never asked, not that the rate is zero. None of the three trials reported a serious adverse event on either drug.

Why Do the Same Two Drugs Produce Different Numbers Across Trials?

A single additional woman reporting a symptom moves the rate by roughly 2 to 3 percentage points in a 32-to-50-person trial arm, which explains most of the spread above. In the Mejia trial’s 33-woman letrozole-only arm, mood changes went from 1 affected woman to 4 in the 32-woman combination arm — a jump from 3% to 13% that reads as a four-fold increase but rests on three additional people. That is not a reason to dismiss the finding, but it is a reason not to treat any single percentage in this article as a precise, stable number the way a much larger trial’s headline live-birth rate can be treated.

The three trials also are not measuring the same comparison. Wasim and Al-Thuwaynee both compared letrozole against clomiphene as separate, single medications. Mejia compared letrozole alone against letrozole combined with clomiphene — meaning the “letrozole” column in that trial’s row describes a woman taking one drug, and the comparison column describes a woman taking two. A reader combining rows across the table without noticing that difference would wrongly credit or blame clomiphene for numbers that describe combination therapy instead.

What Does Each Side Effect Actually Feel Like?

A percentage on its own does not tell a reader what to watch for. Hot flushes on either drug present as a sudden wave of heat across the face, neck, and chest, sometimes with visible flushing or a few minutes of sweating, that passes on its own within about ten minutes. Fatigue, the symptom that showed the largest letrozole-specific increase, was described in trial follow-up as an unusual tiredness that does not lift with a normal night’s sleep — noticeable enough that 31% of women in the largest trial reported it, but not disabling in any of the three studies. Dizziness is a lightheaded or off-balance feeling, most often on standing up quickly; it affected 22% of the letrozole group in the same trial, roughly double the clomiphene rate.

Headache ranged from a dull, low-grade ache to something disruptive enough to notice during the day, and the two trials that measured it disagreed on direction — one found it slightly more common on letrozole, the other slightly less — with neither difference reaching statistical significance. Mood changes, reported as irritability or a low mood that felt different from a woman’s usual baseline, were the least consistently measured symptom on this page and, per the Mejia trial, the one built on the smallest number of affected women. Nausea, sometimes with vomiting, was reported at similarly low rates — 4% to 9% depending on the trial — regardless of which drug a woman took.

What Is the Real OHSS Rate on Letrozole?

Ovarian hyperstimulation syndrome occurred in just 0.5% of women assigned to letrozole, identical to the rate on older ovulation-inducing drugs, across 10 randomized trials and 1,848 participants pooled in a 2022 Cochrane review rated as high-certainty evidence. That figure describes oral letrozole used on its own, monitored the way the trials monitored it — not letrozole combined with injectable gonadotropins, which carries a materially higher OHSS rate in fertility treatment generally and is a different clinical scenario.

A rate of 0.5% is genuinely low, but OHSS is also the one side effect on this page that can escalate quickly, so it earns a symptom-by-symptom description rather than a single statistic. It shows up as progressive abdominal bloating and pain that builds over days rather than settling, nausea or vomiting that does not pass, a rapid increase in weight of more than a couple of pounds over a day or two, and — in its more severe form — a marked drop in how often someone urinates or new shortness of breath. Because OHSS is a response to ovulation itself rather than to the pills directly, symptoms typically appear in the days after ovulation is confirmed, not while the medication is still being taken.

Is Letrozole’s Side-Effect Profile Better or Worse Than Clomiphene’s?

Across every trial that measured it, hot flushes were less frequent on letrozole than on clomiphene — by 19 percentage points in the largest study — while fatigue and dizziness ran the opposite direction, both higher on letrozole in that same trial. Neither drug came out ahead on every symptom, and none of the three trials reported a serious adverse event on either drug. Note in May 2026, PCOS was renamed polyendocrine metabolic ovarian syndrome, or PMOS, by a global consensus of more than 50 organisations; the underlying drug evidence is unchanged, and this article uses PCOS because that is still the term readers search.

What a side-effect table cannot settle is which trade-off matters more to an individual woman — fewer hot flushes but more fatigue, or the reverse. That is a conversation for the prescribing clinician, not a comparison this page or any single trial can resolve in the abstract. For the efficacy side of the same comparison — success rates, resistance, and what changes which drug a clinician recommends first — see how letrozole and clomiphene compare on effectiveness; the 2023 international guideline addresses that comparison, not tolerability, and leaves side-effect management to the clinician monitoring an individual cycle.

Who Should Be Extra Cautious About These Side Effects?

Anyone with a significant personal history of mood disorders should raise it before starting, specifically because mood-change data here is the thinnest on this page — one trial found it in as few as 1 of 33 women and as many as 4 of 32 in a combination arm, numbers too small to rule confidently in or out. Anyone whose day regularly depends on driving, operating machinery, or sustained balance should know that dizziness affected as many as 22% of women on letrozole in the largest trial, and should plan around the days the medication is taken accordingly. And anyone approaching a fourth, fifth, or later cycle of treatment is relying on evidence that simply was not collected that far out — every trial on this page stopped measuring side effects well before that point.

This article does not cover whether letrozole is working, only what it feels like while it is being tried — when in a cycle ovulation typically occurs on letrozole is a separate question covered elsewhere. If side effects on any medication feel disproportionate to what is described here, or if a monitored cycle is not producing ovulation at all, knowing when to escalate to a specialist is the next practical step, not adjusting the treatment independently.

This is one piece of a larger picture — the complete PCOS fertility hub covers ovulation, diagnosis-linked infertility, and treatment options beyond letrozole and clomiphene.

Common questions